NASDAQ:MRNS

Marinus Pharmaceuticals News Headlines

$14.70
-0.36 (-2.39 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.63
$15.12
50-Day Range
$14.70
$19.25
52-Week Range
$6.44
$20.04
Volume64,443 shs
Average Volume148,902 shs
Market Capitalization$538.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Marinus Pharmaceuticals (NASDAQ MRNS) News Headlines Today

SourceHeadline
 Brokerages Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Post Quarterly Sales of $2.57 Million Brokerages Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Post Quarterly Sales of $2.57 Million
americanbankingnews.com - July 28 at 4:20 AM
Were Hedge Funds Right About Marinus Pharmaceuticals Inc (MRNS)?Were Hedge Funds Right About Marinus Pharmaceuticals Inc (MRNS)?
finance.yahoo.com - July 27 at 8:08 PM
 Brokerages Expect Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Announce Earnings of -$0.68 Per Share Brokerages Expect Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Announce Earnings of -$0.68 Per Share
americanbankingnews.com - July 26 at 5:38 AM
Zacks: Analysts Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Announce Earnings of -$0.68 Per ShareZacks: Analysts Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Announce Earnings of -$0.68 Per Share
americanbankingnews.com - July 26 at 5:38 AM
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) to Post FY2022 Earnings of ($3.80) Per Share, SVB Leerink ForecastsMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) to Post FY2022 Earnings of ($3.80) Per Share, SVB Leerink Forecasts
americanbankingnews.com - July 21 at 7:22 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Down to $18.97Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Down to $18.97
americanbankingnews.com - July 13 at 11:16 AM
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Rating of "Buy" from AnalystsMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - July 13 at 5:42 AM
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.
finance.yahoo.com - July 1 at 8:22 AM
Could The Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ownership Structure Tell Us Something Useful?Could The Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ownership Structure Tell Us Something Useful?
nasdaq.com - June 29 at 7:49 AM
Marinus Pharmaceuticals, Inc. Common Stock (MRNS)Marinus Pharmaceuticals, Inc. Common Stock (MRNS)
nasdaq.com - June 26 at 10:08 AM
Heres Why Were Not Too Worried About Marinus Pharmaceuticals (NASDAQ:MRNS) Cash Burn SituationHere's Why We're Not Too Worried About Marinus Pharmaceuticals' (NASDAQ:MRNS) Cash Burn Situation
finance.yahoo.com - June 15 at 2:21 PM
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue EstimatesMarinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 17 at 9:39 AM
Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference CallMarinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
finance.yahoo.com - May 13 at 1:27 PM
Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021
finance.yahoo.com - May 7 at 12:31 PM
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor ConferencesMarinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
finance.yahoo.com - April 28 at 5:18 PM
If You Had Bought Marinus Pharmaceuticals (NASDAQ:MRNS) Stock A Year Ago, You Could Pocket A 101% Gain TodayIf You Had Bought Marinus Pharmaceuticals (NASDAQ:MRNS) Stock A Year Ago, You Could Pocket A 101% Gain Today
finance.yahoo.com - April 16 at 1:21 PM
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - April 12 at 6:21 PM
Marinus Pharmaceuticals Bolsters Leadership Team with Two New AppointmentsMarinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
finance.yahoo.com - April 12 at 8:21 AM
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue EstimatesMarinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 9 at 2:28 PM
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for CommercializationMarinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization
finance.yahoo.com - February 23 at 8:06 AM
What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
finance.yahoo.com - February 15 at 9:34 AM
Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status EpilepticusMarinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus
finance.yahoo.com - January 26 at 9:49 AM
MRNS Feb 2021 14.000 callMRNS Feb 2021 14.000 call
in.finance.yahoo.com - January 23 at 6:32 PM
MRNS Feb 2021 16.000 callMRNS Feb 2021 16.000 call
in.finance.yahoo.com - January 20 at 5:23 PM
MRNS Feb 2021 11.000 putMRNS Feb 2021 11.000 put
in.finance.yahoo.com - January 20 at 5:23 PM
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in ...Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in ...
businesswire.com - January 13 at 11:05 PM
Stock Alert: Marinus Pharmaceuticals Climbs 11%Stock Alert: Marinus Pharmaceuticals Climbs 11%
nasdaq.com - January 13 at 1:04 PM
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)
finance.yahoo.com - January 13 at 8:01 AM
MRNS Jan 2021 8.000 putMRNS Jan 2021 8.000 put
ca.finance.yahoo.com - January 7 at 12:30 AM
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceMarinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 6 at 9:29 AM
5 Disruptive Biotech Stocks With Solid Long-Term Potential5 Disruptive Biotech Stocks With Solid Long-Term Potential
finance.yahoo.com - January 4 at 12:58 PM
MRNS Jan 2021 17.000 putMRNS Jan 2021 17.000 put
in.finance.yahoo.com - December 23 at 10:52 PM
MRNS Jan 2021 10.000 putMRNS Jan 2021 10.000 put
uk.finance.yahoo.com - December 23 at 12:58 AM
MRNS Apr 2021 12.000 callMRNS Apr 2021 12.000 call
uk.finance.yahoo.com - December 22 at 3:15 AM
MRNS Apr 2021 11.000 putMRNS Apr 2021 11.000 put
uk.finance.yahoo.com - December 21 at 10:15 PM
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology IndexMarinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index
finance.yahoo.com - December 21 at 7:11 AM
MRNS Apr 2021 7.000 callMRNS Apr 2021 7.000 call
uk.finance.yahoo.com - December 20 at 9:09 PM
MRNS Jan 2022 12.000 putMRNS Jan 2022 12.000 put
uk.finance.yahoo.com - December 20 at 9:09 PM
Is MRNS A Good Stock To Buy Now?Is MRNS A Good Stock To Buy Now?
finance.yahoo.com - December 14 at 12:34 PM
Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on TuesdayWhy Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday
finance.yahoo.com - December 8 at 10:08 PM
Marinus Pharmaceuticals plans $70M stock saleMarinus Pharmaceuticals plans $70M stock sale
bizjournals.com - December 8 at 5:07 PM
Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common StockMarinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock
finance.yahoo.com - December 8 at 5:07 PM
Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate UpdateMarinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update
finance.yahoo.com - December 7 at 5:41 PM
Marinus Pharmaceuticals Announces Underwritten Public Offering of Common StockMarinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock
finance.yahoo.com - December 7 at 5:41 PM
Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency DisorderMarinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder
finance.yahoo.com - December 7 at 7:24 AM
Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020
finance.yahoo.com - December 2 at 8:27 AM
MRNS Dec 2020 14.000 putMRNS Dec 2020 14.000 put
uk.finance.yahoo.com - November 30 at 4:51 PM
MRNS Dec 2020 10.000 putMRNS Dec 2020 10.000 put
uk.finance.yahoo.com - November 29 at 10:47 PM
MRNS Dec 2020 19.000 callMRNS Dec 2020 19.000 call
uk.finance.yahoo.com - November 28 at 8:46 AM
Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual MeetingMarinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting
finance.yahoo.com - November 23 at 5:41 PM
This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.